Physician profile
Richard L Risher
NPI 1639264021
$3,964.03
in general payments reported to CMS, 2019-2025
36 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.09 · 2021: $111 · 2023: $224 · 2024: $1,590 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,836.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.30 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $533.76 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $454.75 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $371.06 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $224.04 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $175.26 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Axsome Therapeutics, INC. | $168.58 | 2024-2025 | Auvelity, Symbravo |
| Pfizer INC. | $134.10 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $119.38 | 2024-2025 | Gemtesa |
| Pear Therapeutics (US), INC. | $111.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.88 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.10 | 2024-2025 | Jardiance |
| Amgen INC. | $60.66 | 2024-2025 | Evenity, Prolia |
| Alkermes, INC. | $60.03 | 2025 | Vivitrol |
| Abbott Laboratories | $58.95 | 2024-2025 | Freestyle Libre 3 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $54.79 | 2024-2025 | Prolastin-C Liquid |
| Dexcom, INC. | $52.14 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.61 | 2025 | Caplyta |
| Tolmar, INC. | $50.50 | 2025 | Jatenzo |
| Exact Sciences Corporation | $49.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $48.98 | 2025 | |
| Lundbeck LLC | $40.82 | 2025 | Rexulti |
| Radius Health, INC. | $39.99 | 2025 | Tymlos |
| Otsuka America Pharmaceutical, INC. | $39.37 | 2025 | Rexulti |
| Corcept Therapeutics | $32.95 | 2025 | Korlym |
| Astellas Pharma US INC | $31.77 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $31.48 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.76 | 2025 | Trintellix |
| Hologic Sales and Service, LLC | $24.48 | 2025 | Thinprep 2000 Processor, Aptima |
| Endogastric Solutions, INC | $23.27 | 2024 | Esophyx |
| Aimmune Therapeutics, INC. | $19.07 | 2023 | |
| Baxter Healthcare | $17.09 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $16.09 | 2020 | |
| Merck Sharp & Dohme LLC | $15.45 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Kowa Pharmaceuticals America, INC. | $14.59 | 2025 | Zoryve |
| 3b Medical, INC. | $14.34 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Risher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.